tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Mar;28(3):753-756.
doi: 10.3201/eid2803.212210.
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
Seonju Yi, Young June Choe, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, Young-Joon Park
Abstract
We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
Keywords: COVID-19; SARS-CoV-2; South Korea; breakthrough; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine; viruses; zoonoses.
. 2022 Mar;28(3):753-756.
doi: 10.3201/eid2803.212210.
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
Seonju Yi, Young June Choe, Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, Young-Joon Park
- PMID: 35202529
- DOI: 10.3201/eid2803.212210
Abstract
We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
Keywords: COVID-19; SARS-CoV-2; South Korea; breakthrough; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine; viruses; zoonoses.
